SG11202105540YA - 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same - Google Patents

3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same

Info

Publication number
SG11202105540YA
SG11202105540YA SG11202105540YA SG11202105540YA SG11202105540YA SG 11202105540Y A SG11202105540Y A SG 11202105540YA SG 11202105540Y A SG11202105540Y A SG 11202105540YA SG 11202105540Y A SG11202105540Y A SG 11202105540YA SG 11202105540Y A SG11202105540Y A SG 11202105540YA
Authority
SG
Singapore
Prior art keywords
difluoroallylamines
salts
same
pharmaceutical compositions
pharmaceutical
Prior art date
Application number
SG11202105540YA
Inventor
Tae Dong Han
Hee Jae Tak
Eun Kyung Kim
Eui Chul Lee
Sol Park
Hyok Jun Cho
Cheol Hee Lim
So Young Kim
Hyun Ho Choi
Da Na Jeong
Na Yeon Yang
Na Ry Ha
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180161725A external-priority patent/KR20200073499A/en
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of SG11202105540YA publication Critical patent/SG11202105540YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
SG11202105540YA 2018-12-14 2019-12-12 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same SG11202105540YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180161725A KR20200073499A (en) 2018-12-14 2018-12-14 Novel 3,3-difluoroallylamine derivatives or its salt and pharmaceutical compositions comprising the same
KR20190137387 2019-10-31
PCT/IB2019/060736 WO2020121261A1 (en) 2018-12-14 2019-12-12 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same

Publications (1)

Publication Number Publication Date
SG11202105540YA true SG11202105540YA (en) 2021-06-29

Family

ID=71076841

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105540YA SG11202105540YA (en) 2018-12-14 2019-12-12 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same

Country Status (19)

Country Link
US (2) US11168073B2 (en)
EP (1) EP3894398A4 (en)
JP (2) JP7201817B2 (en)
KR (2) KR102615551B1 (en)
CN (1) CN113330001A (en)
AU (2) AU2019398910B2 (en)
BR (1) BR112021010341A2 (en)
CA (1) CA3120240A1 (en)
CL (1) CL2021001536A1 (en)
CO (1) CO2021007648A2 (en)
CR (1) CR20210308A (en)
DO (1) DOP2021000111A (en)
IL (1) IL283539A (en)
MX (1) MX2021007069A (en)
PE (1) PE20211770A1 (en)
PH (1) PH12021551268A1 (en)
SG (1) SG11202105540YA (en)
UA (1) UA126055C2 (en)
WO (1) WO2020121261A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190110740A (en) 2018-03-21 2019-10-01 주식회사유한양행 Novel aryl or heteroaryl triazolone derivatives or its salt and pharmaceutical compositions comprising the same
KR20190110736A (en) 2018-03-21 2019-10-01 주식회사유한양행 Novel triazolone derivatives or its salt and pharmaceutical compositions comprising the same
KR20200004036A (en) 2018-07-03 2020-01-13 주식회사유한양행 Processes for preparing (E)-(2-(chloromethyl)-3-fluoroallyl)carbamate derivatives
CR20210308A (en) 2018-12-14 2021-08-30 Yuhan Corp 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
TW202039486A (en) 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same
MX2021014441A (en) 2019-05-31 2022-01-06 Ikena Oncology Inc Tead inhibitors and uses thereof.
KR20220145981A (en) * 2021-04-22 2022-11-01 주식회사유한양행 Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same
WO2023245329A1 (en) * 2022-06-20 2023-12-28 Biofront Ltd Multi-kinase inhibitors, compositions thereof, and methods of using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725148A1 (en) 1977-06-03 1978-12-14 Hoechst Ag 1-ARYL-4-ALKYL-1,2,4-TRIAZOL-5-ONE AND METHOD FOR THE PRODUCTION THEREOF
WO2005014530A2 (en) * 2003-08-08 2005-02-17 La Jolla Pharmaceutical Co. Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases
KR100572996B1 (en) 2003-08-12 2006-04-25 한국화학연구원 Antifungal azole compounds having fluorovinyl ether group as side chain and process for the preparing same
US7572808B2 (en) 2005-06-17 2009-08-11 Bristol-Myers Squibb Company Triazolopyridine cannabinoid receptor 1 antagonists
US20070293548A1 (en) * 2006-03-31 2007-12-20 Wang Eric Y Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases
WO2008118414A1 (en) 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
CN101657433A (en) 2007-03-29 2010-02-24 弗·哈夫曼-拉罗切有限公司 Non-nucleoside reverse transcriptase inhibitors
GB0722075D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
SG186008A1 (en) 2007-11-21 2012-12-28 Pharmaxis Ltd Haloallylamine inhibitors of ssao/vap-1 and uses therefor
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
WO2013134562A1 (en) 2012-03-09 2013-09-12 Inception 2, Inc. Triazolone compounds and uses thereof
US9192617B2 (en) * 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2844637T (en) 2012-05-02 2018-04-17 Boehringer Ingelheim Int Substituted 3-haloallylamine inhibitors of ssao and uses thereof
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
JP2017537946A (en) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． Substituted heterocycles as bromodomain inhibitors
WO2016101119A1 (en) 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
TW201722958A (en) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 Chemical compounds
AU2017217238B2 (en) 2016-02-12 2021-05-20 Pharmaxis Ltd. Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
US10525041B2 (en) * 2016-05-03 2020-01-07 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2018027892A1 (en) * 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
EA201990951A1 (en) 2016-10-19 2019-11-29 COMBINATIONS CONTAINING SSAO / VAP-1 INHIBITOR AND SGLT2 INHIBITOR, AND THEIR APPLICATION
US20200069648A1 (en) 2017-03-02 2020-03-05 Pharmaxis Ltd. Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof
US20200087248A1 (en) * 2017-04-28 2020-03-19 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fluoroallylamine Derivative And Use Thereof
FI3626699T3 (en) * 2017-06-20 2023-08-15 Shandong Danhong Pharmaceutical Co Ltd Ssao inhibitor
CN109810041B (en) * 2017-11-21 2023-08-15 药捷安康(南京)科技股份有限公司 Halogenated allylamine SSAO/VAP-1 inhibitor and application thereof
CN109988109B (en) * 2017-12-29 2020-12-29 广东东阳光药业有限公司 Amine compound for inhibiting SSAO/VAP-1 and application thereof
KR20190110736A (en) 2018-03-21 2019-10-01 주식회사유한양행 Novel triazolone derivatives or its salt and pharmaceutical compositions comprising the same
KR20190110740A (en) 2018-03-21 2019-10-01 주식회사유한양행 Novel aryl or heteroaryl triazolone derivatives or its salt and pharmaceutical compositions comprising the same
CN110938059A (en) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 Preparation and application of aminourea sensitive amine oxidase inhibitor
WO2020063854A1 (en) 2018-09-27 2020-04-02 南京明德新药研发有限公司 Quinoline-based derivatives as vap-1 inhibitors
MX2021003731A (en) 2018-09-28 2021-08-05 Acucela Inc Inhibitors of vap-1.
CN113164454A (en) 2018-09-28 2021-07-23 奥克塞拉有限公司 Inhibitors of VAP-1
WO2020083264A1 (en) 2018-10-22 2020-04-30 广东东阳光药业有限公司 Guanidine derivative and uses thereof
AU2019365213A1 (en) 2018-10-24 2021-06-03 Metacrine, Inc. SSAO inhibitors and uses thereof
TW202039486A (en) * 2018-12-14 2020-11-01 南韓商柳韓洋行股份有限公司 Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same
CR20210308A (en) * 2018-12-14 2021-08-30 Yuhan Corp 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
EP3892621A4 (en) 2019-01-11 2022-02-09 Nanjing Transthera Biosciences Co., Ltd. Haloallylamine compounds and application thereof
KR20220145981A (en) * 2021-04-22 2022-11-01 주식회사유한양행 Triazolones, tetrazolones, and imidazolones, or their salts, and pharmaceutical compositions comprising the same

Also Published As

Publication number Publication date
KR102615551B1 (en) 2023-12-20
US11168073B2 (en) 2021-11-09
PE20211770A1 (en) 2021-09-07
KR20210092312A (en) 2021-07-23
EP3894398A4 (en) 2022-09-14
CA3120240A1 (en) 2020-06-18
UA126055C2 (en) 2022-08-03
EP3894398A1 (en) 2021-10-20
MX2021007069A (en) 2021-10-01
US20200223827A1 (en) 2020-07-16
JP7201817B2 (en) 2023-01-10
CN113330001A (en) 2021-08-31
CL2021001536A1 (en) 2022-01-21
PH12021551268A1 (en) 2021-10-25
AU2022288984A1 (en) 2023-02-02
JP2022173583A (en) 2022-11-18
AU2019398910B2 (en) 2022-09-22
US20230044255A1 (en) 2023-02-09
AU2019398910A1 (en) 2021-06-10
TW202039447A (en) 2020-11-01
JP2022512398A (en) 2022-02-03
CO2021007648A2 (en) 2021-07-30
CR20210308A (en) 2021-08-30
WO2020121261A1 (en) 2020-06-18
BR112021010341A2 (en) 2021-08-24
KR20240000621A (en) 2024-01-02
DOP2021000111A (en) 2021-09-30
IL283539A (en) 2021-07-29
US11713308B2 (en) 2023-08-01

Similar Documents

Publication Publication Date Title
IL283539A (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
IL289925A (en) Adenosine derivative and pharmaceutical composition comprising the same
SG11202011685QA (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
IL276952A (en) 2,4-diaminoquinazoline derivatives and medical uses thereof
EP3894408A4 (en) Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same
PT3580208T (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
EP3768675A4 (en) Novel triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same
SG11202112111WA (en) Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
IL272055A (en) 1,8-naphthyridinone compounds and uses thereof
HK1257989B (en) 1,3-disubstituted ketene compounds and applications thereof
IL289932A (en) 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
IL284765A (en) 1,8-naphthyridinone compounds and uses thereof
EP3539978A4 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
SG11202105012VA (en) Aromatic ring-linked dioxino-quinazoline or dioxino-quinoline compounds, compositions and use thereof
EP3448839A4 (en) Quinazoline derivative or its salt and pharmaceutical composition comprising the same
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
EP3715344A4 (en) 1,4-benzodiazapin-2-one derivatives and use thereof
IL282999A (en) 1,3,4-oxadiazolone compound and pharmaceutical
IL282142A (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament
PL3778609T3 (en) Penam derivatives or salts thereof, pharmaceutical compositions and use thereof
GB201905509D0 (en) Pharmaceutical compositions and associated lits and uses
KR102483492B9 (en) 25- 25-disubstituted pyrimidines and pharmaceutical composition comprising the same
GB201902721D0 (en) The infinity project
GB201902087D0 (en) Medicament and the use thereof